Business Wire

Thales Unveils PureFlyt, the Brain of Tomorrow’s Aircraft

25.11.2019 21:33:00 EET | Business Wire | Press release

Share

Innovdays -Thales is unveiling PureFlyt, the Flight Management System (FMS) of the future, specifically designed to efficiently manage aircraft in a connected aerospace ecosystem and in increasingly crowded skies. Indeed, with the global commercial aircraft fleet forecast to double by 2030, and the use of drones set to rapidly grow, we will be entering an era in which millions of aircraft movements are recorded each day.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005715/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

© Thales

Combining extensive knowledge of Avionics, Connectivity, Air Traffic management and 40-year Flight Management System expertise, Thales has developed PureFlyt, an entirely connected FMS, designed to offer airframers and airlines the best combination of safety, security, and fuel and operations efficiency. PureFlyt will allow crews to make better decisions using more sources of information, will bring improved performance and reactivity to the aircraft during complex phases of flight and will calculate alternative trajectories in real time to propose or react quickly to changes of plan. Providing pilots with the right information at the right time heightens trust in the computed trajectory, enhancing efficiency and reducing pilot workload throughout all flight phases.

One of the core innovations making PureFlyt a game changer in the FMS world is its ability to draw on both onboard and open-world data, such as weather information. By combining the integrity of the FMS and the agility and power of Electronic Flight Bag flight functionalities, aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and improved passenger comfort.

While being a technological breakthrough, PureFlyt enjoys an unparalleled maturity level. Using massive testing and artificial intelligence technologies to simulate 2 billion test cases enabled accumulating an invaluable experience, equivalent of 100 million actual flight hours.

Cyber-secure by design, PureFlyt has also been designed to be future-proof, accommodating the implementation of concepts such as the Initial 4D (I4D) trajectory management methods currently being researched by SESAR (Single European Sky ATM Research) in the EU and NextGen in the US. By increasing the accuracy of flight in four dimensions, the fourth dimension being time, PureFlyt will enable more effectiveness in maintaining optimal distance between aircraft, particularly in the demanding phases of departure and approach.

PureFlyt will be available for entry into service in 2024, for both linefit and retrofit.

“In the air, the digital revolution has only just begun. A paradigm shift in onboard cockpit electronics is taking place in the connected airspace and PureFlyt is at the forefront of this digital new age, leading the next generation of Flight Management System that truly makes the aircraft a node of connectivity. By computing and sharing vast amounts of data, PureFlyt will make flights safer, greener, easier for the pilots to manage, more profitable for airlines and, all this, ultimately for the full benefits of passengers” declared Jean-Paul Ebanga, Thales Vice-President Flight Avionics.

For more information please visit:
https://www.thalesgroup.com/en/group/magazine/quantum-leap-flight-management

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way.

Thales generated revenues of €19 billion in 2018 with 80,000 employees in 68 countries.

PLEASE VISIT

Thales Group
Thales Press
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS
Thales, Media Relations
Civil Aerospace
Giaime Porcu
+33 1 57 77 92 18
giaime.porcu@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye